William N. Starling is Managing Director of Synergy Life Science Partners, LP (www.synergylsp.com
) a $143 million Venture Capital Partnership and Chief Executive Officer of Synecor, LLC, (Synecor) a business generator of new Life Science companies based in Research Triangle Park (RTP), North Carolina. Synecor (www.synecor.com
) has significant academic, scientific, physician, venture capital, corporate, and investment banking partnerships and is focusing its efforts on the identification and development of proprietary, disruptive technologies with extraordinary market potential in the life sciences field.
As CEO of Synecor, Mr. Starling is a cofounder of BaroSense, Inc., Bioerodible Vascular Solutions, Inc., (BVS, acquired by Guidant/Abbott in March 2003), InnerPulse, Inc., TransEnterix, Inc. (NYSE:TRXC), Interventional Autonomics Corporation, NeuroTronik Limited, Aegis Surgical Limited, and Atrius Limited the initial eight companies founded and incubated by Synecor. Mr. Starling currently serves as President and CEO of Aegis Surgical Limited, and Atrius Limited, both Irish-based companies in the structural heart field; Chairman of the Board of Interventional Autonomics Corporation, and as a board member of TransEnterix, Inc. (NYSE: TRXC), a RTP, NC – based surgery company developing the world’s first patient-side robotic surgical system for single incision surgery. Mr. Starling is also on the Board of iRhythm Technologies, Inc. in San Francisco, a Stanford BioDesign spinout that Synergy Life Science Partners has funded since its inception in 2007.
William N. Starling began his 38-year career in the medical technology device industry at American Edwards Laboratories (Edwards LifeSciences – NYSE:EW). He was subsequently part of the founding management team and Director of Marketing for Advanced Cardiovascular Systems, Inc. (acquired by Guidant/Abbott), and was a cofounder, Vice President and Board member of Ventritex, Inc. (IPO in 1992, acquired by St. Jude Medical in 1997). Mr. Starling was a cofounder and Chairman of the Board of Directors and President/CEO of Cardiac Pathways Corporation (IPO in 1996, acquired by Boston Scientific Corporation in 2001). The start-up companies he has co-founded today represent over $4 billion in annual revenues and Mr. Starling is responsible for raising over $235M in private and public capital for these development stage companies.
Mr. Starling serves on the Stanford Stroke Center’s Board of Advisors at the Stanford University Medical Center. He also serves on the Kenan-Flagler Business School Board of Visitors (Chairman 2009-2014), Chairman of the UNC/NCSU Department of Biomedical Engineering Industry Advisory Board and the Chancellor’s Innovation Circle at the University of North Carolina at Chapel Hill where he frequently guest lectures to undergraduate and graduate students on entrepreneurism.